News | EP Lab | January 05, 2022

Stereotaxis Robotics Reduces Incidence of Silent Cerebral Embolism During AF Ablation

Stereotaxis Robotics Reduces Incidence of Silent Cerebral Embolism During AF Ablation

January 5, 2022 — Stereotaxis announced a recent publication in Frontiers in Cardiovascular Medicine titled “Atrial Fibrillation Ablation Using Robotic Magnetic Navigation Reduces the Incidence of Silent Cerebral Embolism. This multi-center, prospective study evaluated 166 patients with paroxysmal or persistent atrial fibrillation (AF) who underwent pulmonary vein isolation using either Stereotaxis’ Robotic Magnetic Navigation (RMN) technology or manual contact force ablation catheters.

All patients received cerebral magnetic resonance imaging within 48 hours before and after the ablation procedure to assess cerebral embolism. Patients treated using RMN had greater than 82% reduced incidence of silent cerebral embolism (SCE) at 5.77% compared to 32.26% in patients treated with manual catheter ablation (p<0.001). The study concluded, “ablation technology is the only independent risk factor of SCEs, and RMN can significantly reduce the incidence of SCEs resulting from AF ablation.” This is the first study comparing incidence of SCEs following cardiac ablation with RMN compared to manual catheters and was performed independent of Stereotaxis in China by Wuxi People’s Hospital, Fuwai Hospital, Xuzhou Central Hospital, and the First Hospital Affiliated to Soochow University.

“The results of this study further strengthen the significant safety and efficacy benefits we have experienced using robotic technology to treat over 600 arrhythmia patients,” said Dr. Ru-Xing Wang, director of cardiology at Wuxi People’s Hospital. “We are grateful to offer our patients the best possible care and look forward to advance clinical research and robotic technology development.”

“This pioneering research on an often overlooked aspect of cardiac ablation demonstrates that technology innovation can meaningfully improve patient safety,” said Dr. Yan Yao, Director of the Arrhythmia Center at Fuwai Hospital. “This strong data supports our decision to build a world-class robotic cardiac center of excellence in Beijing.”

Stereotaxis’ Robotic Magnetic Navigation technology introduces the benefits of robotic precision and safety to cardiac ablation, a common, minimally invasive procedure to treat arrhythmias. Multiple studies have demonstrated reduced incidences of heart perforation and other major adverse events from the use of robotics for cardiac ablation when compared to manual hand-held catheters. This is the first study assessing the impact of robotics on silent cerebral emboli. Studies have demonstrated that incurring acute cerebral lesions during cardiac ablation procedures may be associated with longer-term adverse neuropsychological outcomes such as an increased risk of stroke and cognitive impairment.

Read the full article

For more information: www.RoboticEP.com/clinical-data/publications-database/


Related Content

Feature | EP Lab | By Vijay Kundekar

Arrhythmias can be described as irregular heart rhythms that are brought on by numerous factors, including heart damage ...

Home August 23, 2022
Home
News | EP Lab

May 24, 2022 — Attune Medical, a pioneering medical device company with a technology platform based on temperature ...

Home May 24, 2022
Home
News | EP Lab

May 4, 2022 — CathVision, a medical technology company developing innovative electrophysiology solutions designed to ...

Home May 04, 2022
Home
News | EP Lab

April 27, 2022 – CathVision, a medical technology company developing innovative electrophysiology solutions designed to ...

Home April 27, 2022
Home
News | EP Lab

Royal Philips, a global leader in health technology, announced late-breaking results of a large-scale, real-world ...

Home April 12, 2022
Home
News | EP Lab

January 14, 2022 — Medtronic has entered into a definitive agreement to acquire Affera Inc., a Boston area-based ...

Home January 14, 2022
Home
News | EP Lab

January 13, 2022 — Abbott received U.S. Food and Drug Administration (FDA) clearance for the EnSite X EP System with ...

Home January 13, 2022
Home
News | EP Lab

January 7, 2022 — Khaldoun Tarakji, M.D., M.P.H., associate section head of cardiac electrophysiology at the Heart ...

Home January 07, 2022
Home
Feature | EP Lab

Children’s Hospital Los Angeles cardiologist Michael Silka, M.D., helped to pioneer the development of indications for ...

Home December 07, 2021
Home
News | EP Lab

November 22, 2021 — BioSig Technologies Inc., a medical technology company commercializing an innovative biomedical ...

Home November 22, 2021
Home
Subscribe Now